Litcius/Paper detail

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

Marc‐Oliver Grimm, Emilio Esteban, Philippe Barthélémy, Manuela Schmidinger, Jonas Busch, Begoña P. Valderrama, Natalie Charnley, Marc Schmitz, Ulrike Schumacher, Katharina Leucht, Susan Foller, Gustavo Baretton, Ignacio Durán, Guillermo de Velasco, Frank Priou, Pablo Maroto, Laurence Albigès, C. Barone, Daniel Castellano, Christine Chevreau, P. Gajate Borau, Srinavasan Gopalakrishnan, Enrique Grande, Abdel Hamid, Julia Heinzelbecker, Martin Janssen, Jindřich Kopecký, Eugen Kubala, Wolfgang Loidl, Anja Lorch, Bohuslav Melichar, Nuria Laínez Milagro, Günter Niegisch, Carsten‐Henning Ohlmann, Anne Sacré, Naveed Sarwar, Giovanni Schinzari, Dirk Schrijvers, Sophie Tartas, Manfred Wirth, Pascal Wolter, Milanda Zemanova

2023The Lancet Oncology34 citationsDOI

Topics & Concepts

NivolumabMedicineIpilimumabRenal cell carcinomaInternal medicineClinical endpointOncologyPopulationResponse Evaluation Criteria in Solid TumorsPhases of clinical researchProgressive diseaseSurgeryCancerClinical trialImmunotherapyChemotherapyEnvironmental healthRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis